ArticleEndocrine2016
Two-miRNA classifiers differentiate mutation-negative follicular thyroid carcinomas and follicular thyroid adenomas in fine needle aspirations with high specificity.
Article in Endocrine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- A systematic review of emerging RNA markers in thyroid fine needle aspiration cytology samples: advancements and challenges.Endocrine · 2025Pooled it
- Inducer microRNAs in the glioma development: a concise review of mechanisms and insights into targeted therapy.Journal of the Egyptian National Cancer Institute · 2025Review
- MicroRNA Profiling in Papillary Thyroid Cancer.International journal of molecular sciences · 2024Article
- Article
- Diagnosis of Prostate Cancer through the Multi-Ligand Binding of Prostate-Derived Extracellular Vesicles and miRNA Analysis.Life (Basel, Switzerland) · 2023Article
- miR-484: A Potential Biomarker in Health and Disease.Frontiers in oncology · 2022Review
- Modulatory role of miRNAs in thyroid and breast cancer progression and insights into their therapeutic manipulation.Current research in pharmacology and drug discovery · 2022Review
- Reciprocal Dysregulation of MiR-146b and MiR-451 Contributes in Malignant Phenotype of Follicular Thyroid Tumor.International journal of molecular sciences · 2020Article
- Molecular Markers Guiding Thyroid Cancer Management.Cancers · 2020Review
- Differential MicroRNA-Signatures in Thyroid Cancer Subtypes.Journal of oncology · 2020Review
- Update on Fundamental Mechanisms of Thyroid Cancer.Frontiers in endocrinology · 2020Review
- Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome.Cancers · 2019Review
- In Silico Integration Approach Reveals Key MicroRNAs and Their Target Genes in Follicular Thyroid Carcinoma.BioMed research international · 2019Article
- miR-484/MAP2/c-Myc-positive regulatory loop in glioma promotes tumor-initiating properties through ERK1/2 signaling.Journal of molecular histology · 2018Article
- Integrated microRNA-mRNA analyses of distinct expression profiles in follicular thyroid tumors.Oncology letters · 2017Article
- Molecular profiling of thyroid nodule fine-needle aspiration cytology.Nature reviews. Endocrinology · 2017Review
- Thyroid nodules and cancer management guidelines: comparisons and controversies.Endocrine-related cancer · 2017Review
- MicroRNAs as Biomarkers in Thyroid Carcinoma.International journal of genomics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnosis of thyroid by fine needle aspiration is challenging for the "indeterminate" category and can be supported by molecular testing. We set out to identify miRNA markers that could be used in a diagnostic setting to improve the discrimination of mutation-negative indeterminate fine needle aspirations. miRNA high-throughput sequencing was performed for freshly frozen tissue samples of 19 RAS and PAX8/PPARG mutation-negative follicular thyroid carcinomas, and 23 RAS and PAX8/PPARG mutation-negative follicular adenomas. Differentially expressed miRNAs were validated by quantitative polymerase chain reaction in a set of 44 fine needle aspiration samples representing 24 follicular thyroid carcinomas and 20 follicular adenomas. Twenty-six miRNAs characterized by a significant differential expression between follicular thyroid carcinomas and follicular adenomas were identified. Nevertheless, since no single miRNA had satisfactory predictive power, classifiers comprising two differentially expressed miRNAs were designed with the aim to improve the classification. Six two-miRNA classifiers were established and quantitative polymerase chain reaction validated in fine needle aspiration samples. Four out of six classifiers were characterized by a high specificity (≥94 %). The best two-miRNA classifier (miR-484/miR-148b-3p) identified thyroid malignancy with a sensitivity of 89 % and a specificity of 87 %. The high-throughput sequencing allowed the identification of subtle differences in the miRNA expression profiles of follicular thyroid carcinomas and follicular adenomas. While none of the differentially expressed miRNAs could be used as a stand-alone malignancy marker, the validation results for two-miRNA classifiers in an independent set of fine needle aspirations are very promising. The ultimate evaluation of these classifiers for their capability of discriminating mutation-negative indeterminate fine needle aspirations will require the evaluation of a sufficiently large number of fine needle aspirations with histological confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.